STIL and ovarian carcinoma: Indeed, knockdown of STIL significantly enhanced the sensitivity to cisplatin in HeyA8, IGROV1 and RMG1 ovarian cancer cells (Figure 2D–2F) reducing the IC50 from a mean of 19μM (range: 13.3-30μM) to 6μM (range: 3.3-10μM; P<0.01 two tailed T-test).